Anuj Mahindra

Author PubWeight™ 8.27^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Management of relapsed and relapsed/refractory multiple myeloma.	J Natl Compr Canc Netw	2011	0.98
2	Novel therapies in the treatment of multiple myeloma.	J Natl Compr Canc Netw	2009	0.93
3	Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.	Clin Cancer Res	2011	0.93
4	Therapeutic strategies for the treatment of multiple myeloma.	Discov Med	2013	0.82
5	Novel immunomodulatory compounds in multiple myeloma.	Expert Opin Investig Drugs	2012	0.81
6	Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target?	J Natl Cancer Inst	2012	0.80
7	Lenalidomide: the emerging role of a novel targeted agent in malignancies.	Drugs Today (Barc)	2007	0.80
8	The treatment of multiple myeloma patients not eligible for asct.	Mediterr J Hematol Infect Dis	2010	0.78
9	Conflicts of interest, authorship, and disclosures in industry-related scientific publications.	Mayo Clin Proc	2010	0.75
10	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.	Eur J Haematol	2011	0.75